Details

<p>List of Contributors viii</p> <p>Preface xii</p> <p><b>Part 1 Introduction</b></p> <p>1 Concept and Scope of Modern Vaccines 3<br /><i>D. Huw Davies, Clint S. Schmidt, & Nadeem A. Sheikh</i></p> <p><b>Part 2 Principles of Vaccine Design</b></p> <p>2 Strategies to Stimulate Innate Immunity for Designing Effective Vaccine Adjuvants 15<br /><i>Heather L. Wilson, Scott Napper, George K. Mutwiri, Sylvia van Drunen Littel-van den Hurk, Hugh Townsend, Lorne A. Babiuk, Andrew A. Potter, & Volker Gerdts</i></p> <p>3 Antigen Processing and Presentation by MHC Class I, II, and Nonclassical Molecules 29<br /><i>Antony N. Antoniou, Izabela Lenart, David B. Guiliano, & Simon J. Powis</i></p> <p>4 Understanding the Mucosal Immune System for Better Mucosal Vaccine Design 47<br /><i>Janine Bilsborough & Joanne L. Viney</i></p> <p>5 Immunologic Memory: T Cells in Humans 61<br /><i>Maria Candela Iglesias, Victor Appay, & Arnaud Moris</i></p> <p>6 Immunologic Memory: B cells 79<br /><i>F. Eun-Hyung Lee & Iñaki Sanz</i></p> <p>7 Utility of Mouse Models in Vaccine Design and Development 94<br /><i>Catharine M. Bosio, Megan MacLeod, Philippa Marrack, & Ross M. Kedl</i></p> <p>8 Utility of Nonhuman Primate Models for Vaccines 110<br /><i>Preston A. Marx, Jr & Alexander F. Voevodin</i></p> <p><b>Part 3 Antigen Discovery</b></p> <p>9 Sequence-Based Computational Approaches to Vaccine Discovery and Design 133<br /><i>Darrick Carter</i></p> <p>10 Antigen Discovery for Vaccines Using High-throughput Proteomic Screening Technologies 150<br /><i>D. Huw Davies</i></p> <p>11 Phage Libraries 168<br /><i>Aaron K. Sato</i></p> <p><b>Part 4 Antigen Engineering</b></p> <p>12 Attenuated Bacterial Vaccines 181<br /><i>Richard W. Titball & Helen S. Atkins</i></p> <p>13 Virus-like Particles as Antigen Scaffolds 196<br /><i>Bryce Chackerian & John T. Schiller</i></p> <p>14 Recombinant MVA vaccines: Optimization, Preclinical, and Product Development 209<br /><i>Yper Hall & Miles W. Carroll</i></p> <p>15 Recombinant Adenoviruses for Vaccination 224<br /><i>Nelson Cesar Di Paolo, Dmitry Shayakhmetov, & André Lieber</i></p> <p>16 Recombinant Avipoxviruses 237<br /><i>Michael A. Skinner & Stephen M. Laidlaw</i></p> <p>17 Intracellular Facultative Bacterial Vectors for Cancer Immunotherapy 255<br /><i>Patrick Guirnalda, Laurence Wood, Matthew Seavey, & Yvonne Paterson</i></p> <p>18 Nucleic Acid Vaccination 275<br /><i>Britta Wahren & Margaret A. Liu</i></p> <p>19 Artificial Antigen-presenting Cells: Large Multivalent Immunogens 286<br /><i>Matthew F. Mescher & Julie M. Curtsinger</i></p> <p><b>Part 5 Delivery Systems</b></p> <p>20 Transcutaneous Immunization via Vaccine Patch Delivery System 303<br /><i>Robert C. Seid, Jr & Gregory M. Glenn</i></p> <p>21 Needle-free Jet Injection for Vaccine Administration 324<br /><i>Brian R. Sloat, Hoi K. Tran, & Zhengrong Cui</i></p> <p>22 Oral Vaccines: An Old Need and Some New Possibilities 336<br /><i>Amit A. Lugade, Kalathil Suresh, & Yasmin Thanavala</i></p> <p>23 Adjuvants: From Serendipity to Rational Discovery 348<br /><i>Derek T. O’Hagan & Andreas Wack</i></p> <p>24 Immunostimulatory Properties of Biodegradable Microparticles 361<br /><i>Fiona A. Sharp & Ed C. Lavelle</i></p> <p>25 Co-administration of Co-stimulatory Moieties 375<br /><i>Carolina Arancibia-Cárcamo & Yvette Latchman</i></p> <p>26 Toll Receptors in Relation to Adjuvant Effects 393<br /><i>Dipshikha Chakravortty, Amit Lahiri, & Priyanka Das</i></p> <p><b>Part 6 Regulatory Considerations</b></p> <p>27 Regulatory Issues (FDA and EMA) 403<br /><i>Murrium Ahmad, Victoria Byers, & Peter Wilson</i></p> <p><b>Part 7 Evaluating Vaccine Efficacy</b></p> <p>28 Immune Monitoring Design within the Developmental Pipeline for an Immunotherapeutic or Preventive Vaccine 419<br /><i>Sylvia Janetzki, Pedro Romero, Mario Roederer, Diane L. Bolton, & Camilla Jandus</i></p> <p>29 Clinical Development Strategy: Nuts and Bolts 441<br /><i>Candida Fratazzi & Claudio Carini</i></p> <p>30 Current Approaches to Identify and Evaluate Cancer Biomarkers for Patient Stratification 452<br /><i>Robert Rees, Stephanie Laversin, Cliff Murray, & Graham Ball</i></p> <p><b>Part 8 Implementing Immunizations/Therapies</b></p> <p>31 Mass Immunization Strategies 467<br /><i>David L. Heymann, R. Bruce Aylward, & Rudolf H. Tangermann</i></p> <p>32 The Role of Mathematical Models in Vaccine Development and Public Health Decision Making 480<br /><i>Marie-Claude Boily, Marc Brisson, Benoit Mâsse, & Roy M. Anderson</i></p> <p>33 Vaccine Safety 509<br /><i>John Iskander, Claudia Vellozzi, Jane Gidudu, & Robert T. Chen</i></p> <p>Index 525</p>

<p>“Vaccinology provides an invaluable and authoritative resource for clinicians, scientific and medical researchers, lecturers and postdoctoral fellows working in the field of vaccines.”  (<i>Sir Read A lot</i>, 10 May 2012)</p>

<p><b>W. John W. Morrow</b>, Seattle, Washington, USA</p> <p><b>Nadeem A. Sheikh</b>, Dendreon, Inc., Seattle, Washington, USA</p> <p><b>Clint S. Schmidt</b>, NovaDigm Therapeutics, Inc., Grand Forks, North Dakota, USA</p> <p><b>D. Huw Davies</b>, University of California at Irvine, USA</p>

<p>Covering all aspects of vaccine research and development in one volume, this authoritative resource takes a comprehensive and systematic approach to the science of vaccinology focusing not only on basic science, but also on the many stages required to commercialize and navigate the regulatory requirements for human application, both in the United States and Europe.</p> <ul> <li>Reviews in detail the process of designing a vaccine, from the initial stages of antigen discovery to human application</li> <li>Includes evaluation of vaccine efficacy and safety</li> <li>Details clinical trial design, including regulatory requirements</li> <li>Discusses the emerging field of active cellular immunotherapy</li> </ul> <p><i>Vaccinology: Principles and Practice</i> provides an invaluable resource for clinicians, scientific and medical researchers, lecturers and postdoctoral fellows working in the field of vaccines.</p>

GB